Standard BioTools Inc. (LAB)

Market Cap	603.06M
Revenue (ttm)	155.90M
Net Income (ttm)	-170.60M
Shares Out	372.26M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,933,802
Open	1.620
Previous Close	1.610
Day's Range	1.561 - 1.670
52-Week Range	1.210 - 3.040
Beta	1.57
Analysts	Strong Buy
Price Target	2.88 (+77.78%)
Earnings Date	Oct 30, 2024

About LAB

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology inst...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 10, 2011
• Employees: 539
• Stock Exchange: NASDAQ
• Ticker Symbol: LAB
• Website: https://www.standardbio.com

Financial Performance

In 2023, Standard BioTools's revenue was $106.34 million, an increase of 8.57% compared to the previous year's $97.95 million. Losses were -$74.66 million, -60.73% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for LAB stock is "Strong Buy." The 12-month stock price forecast is $2.88, which is an increase of 77.78% from the latest price.

Price Target

$2.88

(77.78% upside)

Analyst Consensus: Strong Buy